Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO
Year: 2025
Type: article
Study design: Observational Study
Abstract: ABSTRACT: Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging to treat, especially in patients ineligible for intensive therapy or chimeric antigen receptor T cells. Tafasitamab plus lenalidomide (T/L) is an effective option based on the phase 2 L-MIND trial findings, although real-world evidence studies have not consistently confirmed these results. We aimed to describe real-world outcomes of R/R DLBCL treated with T/L in Spain. A total of 99 patients received at least 1 dose of tafasitamab (intent-to-treat [ITT] cohort), with 83 completing at least 1 full cycle of T/L (efficacy cohort). Respectively for ITT and efficacy cohorts, at a median follow-up of 19.2 and 21.6 months, the overall response rate was 51% and 61% (complete response [CR], 35% and 42%). Median duration of response was not reached, and patients achieving a CR had excellent outcomes. The median progression-free survival (PFS) was 4.9 and 10.9 months, and overall survival (OS) was 12.2 and 21.8 months, respectively for both ITT and efficacy cohorts. Neither age nor cumulative illness rating score influenced survival. Better PFS was obtained in first/second relapse but only poor Eastern Cooperative Oncology Group performance status 2 to 4, double-hit lymphoma, and those with refractory/progressing disease after the previous therapy, were independently associated with worse PFS. Treatment was generally well tolerated, with manageable toxicity. Relative dose intensity of lenalidomide significantly affected response, PFS, and OS. In summary, T/L is both well tolerated and effective, irrespective of age or comorbidities. Our findings provide valuable insights into the real-world application of T/L and reinforce its role as a key treatment option for patients with R/R DLBCL.
Source: Blood Advances
Authors: Antonio Gutierrez, Izaskun Zeberio, Francisco Javier Peñalver, Pilar Martinez-Barranco, Sandra Perez, Daniel Morillo, Xabier Martin, Concepcion Nicolas, Ainara Ferrero, Ana Jimenez-Ubieto, Mariana Bastos-Oreiro, Julio Davila-Valls, Maria Victoria Calle, María Perez, Guillermo Rodriguez, Aranzazu Alonso, Ana Garcia-Noblejas, Diana Sanchez Argüello, Teresa Knight, Ángeles Fernandez, Javier Lopez, Jaime Perez De Oteyza, Sonia González de Villambrosia, Elena Perez, Alejandro Marin, Maria Belen Navarro, Ruben Fernandez, Pilar Gomez, José Antonio Hueso, Maria Jesus Peñarrubia Ponce, Pilar Bravo, Daniel Garcia-Belmonte, Haridian De La Nuez, Sara Nistal, Pau Abrisqueta, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio, Maria Stefania Infante, Eva Gonzalez-Barca
Institutions: Health Research Institute of the Balearic Islands, Hospital Universitario Son Espases, Donostiako Unibertsitate Ospitalea, Hospital Universitario Fundación Alcorcón, Hospital Universitario Fundación Jiménez Díaz, Hospital de Cruces, Hospital Universitario Central de Asturias, Hospital Universitari Arnau de Vilanova, Hospital Universitario 12 De Octubre, Hospital General Universitario Gregorio Marañón, Complejo Hospitalario Torrecárdenas, Hospital General de Elda, Hospital Universitario Virgen del Rocío, Hospital Universitario Quirónsalud Madrid, IDCQ Hospitales y Sanidad, S.L.U., Hospital Universitario de La Princesa, Hospital Universitario Lucus Augusti, Complejo Hospitalario de Pontevedra, Hospital General Universitario de Alicante Doctor Balmis, Universidad San Pablo CEU, Hospital Universitario HM Sanchinarro, Marqués de Valdecilla University Hospital, Hospital General Universitario Morales Meseguer, Hospital Universitario Nuestra Señora de Candelaria, Hospital Universitario Puerta de Hierro Majadahonda, Hospital Universitario De Cabueñes, Hospital Universitario La Paz, Hospital Clínico Universitario de Valladolid, Hospital Universitario de Fuenlabrada, Hospital Universitario Sanitas La Zarzuela, Hospital Universitario de Gran Canaria Doctor Negrín, Vall d'Hebron Hospital Universitari, Hospital Vega Baja, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria Aragón, Hospital Universitario Doctor Peset, Fundación Hospital Manacor, Hospital Universitario Infanta Leonor, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitat de Barcelona
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
Funder: Incyte
OpenAlex ID: W4412487234